default author photo

Shuka Furuki

Jichi Medical University - Division of Hematology

SCHOLARLY PAPERS

2

DOWNLOADS

148

TOTAL CITATIONS

0

Scholarly Papers (2)

Actions:
Email selected abstracts
1.

Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/ Refractory Multiple Myeloma

Number of pages: 38 Posted: 22 Feb 2023
Chihiro Yamamoto, Daisuke Minakata, Daizo Yokoyama, Shuka Furuki, Atsuto Noguchi, Shunsuke Koyama, Takashi Oyama, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Shin-ichiro Kawaguchi, Kazuki Hyodo, Yumiko Toda, Shoko Ito, Takashi Nagayama, Kento Umino, Kaoru Morita, Masahiro Ashizawa, Masuzu Ueda, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-ichiro Fujiwara and Yoshinobu Kanda
Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology and Jichi Medical University - Division of Hematology
Downloads 91 (742,061)

Abstract:

Loading...

Multiple myeloma, cost-effectiveness analysis, anti-BCMA CAR-T

2.

Cost-Effectiveness of Blinatumomab as a Post-Remission Therapy for MRD-Negative, Ph-Negative Adult B-ALL Patients

Number of pages: 37 Posted: 22 Aug 2025
Chihiro Yamamoto, Teruaki Yamaguchi, Seina Honda, Ryutaro Tominaga, Daizo Yokoyama, Shuka Furuki, Atsuto Noguchi, Shunsuke Koyama, Rui Murahashi, Hirotomo Nakashima, Shin-ichiro Kawaguchi, Kazuki Hyodo, Yumiko Toda, Kento Umino, Daisuke Minakata, Masahiro Ashizawa, Masuzu Ueda, Kaoru Hatano, Kazuya Sato, Ken Ohmine, Shin-ichiro Fujiwara and Yoshinobu Kanda
Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology, Jichi Medical University - Division of Hematology and Jichi Medical University - Division of Hematology
Downloads 57 (1,000,027)

Abstract:

Loading...

blinatumomab, acute lymphoblastic leukemia, Philadelphia-chromosome negative, cost-effectiveness analysis